BioCardia Inc. - Warrants (26/07/2022)
BCDAW
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.39M
Close$
$-0.27
4521.3% downside
Current Fair Value
4521.3% downsideOvervalued by 4521.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.39 Million |
|---|---|
| Enterprise Value | $4.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.23 |
| Beta | 1.37 |
| Outstanding Shares | 10,812,419 |
Return
| Return on Equity | 729.36% |
|---|---|
| Return on Assets | -454.15% |
| Return on Invested Capital | 520.17% |
Valuation & Multiples
| P/E Ratio | -1.29 |
|---|---|
| PEG | 7.74 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.88 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | -0.39 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioCardia Inc.
27 employees
CEO: Peter Altman BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are ...